BIOMEDICAL DEVELOPMENT CORPORATION

Real World Adoption of an OUD Digital Health Therapeutic

BIOMEDICAL DEVELOPMENT CORPORATION is active in the national institute on drug abuse space based in San Antonio, TX, founded in 1984.

Profile

PROJECT SUMMARY / ABSTRACT
The opioid crisis is an epidemic with devastating health, social, and economic consequences for the United
States. In 2020, 2.7 million people over the age of 12 were reported to suffer from opioid use disorder (OUD).
The total economic burden of the opioid crisis in the US was recently estimated to be nearly $1.5 trillion.
Treatment for OUD involves medication (MOUD) combined with counseling or behavioral therapy to
manage the illness, achieve and sustain better health, and improve quality of life. Rates of recurrent drug use
are high, and access to counseling is limited and costly. While MOUD is standard of care and highly effective
at reducing acute morbidity and mortality, there are advantages to treatment approaches tailored to address an
individual patient’s drug use patterns and drug-related medical, psychiatric, and social problems. While mobile
tools exist to support OUD treatment, these products offer only generalized information and not personalized
feedback that is responsive to each person’s current status to support his/her individual recovery.
In a currently funded NIDA Phase II STTR grant, we are clinically evaluating KIOS, an innovative software
platform using nonlinear control theory, to satisfy requirements for FDA 510(k) device clearance. KIOS is a
digital health therapeutic that tracks multiple interacting symptoms (e.g., cravin

Within the national institute on drug abuse space, the company focuses on its core offering rather than a broad product line.

The business is associated with San Antonio, TX.

Directory data places it at the SBIR/STTR stage.

The company reports a headcount in the 1-10 range.

It has disclosed roughly $778K in funding.

Website: biodevcorp.com